 

Active Ingredient: Alendronate sodium 

 

Dosage Form; Route: Effervescent tablet; oral 

 

Recommended Studies: In vitro dissolution or in vivo study 

 

I. In vitro dissolution option 


 

To demonstrate bioequivalence (BE) via the in vitro dissolution option, a generic alendronate 
sodium effervescent tablet should demonstrate that it is fully dissolved in water at the time of 
administration, per administration instructions provided in the approved drug label, and does not 
contain any excipients that may significantly affect drug absorption and systemic availability. 

 

II. In vivo study option 


 

Type of study: Fasting 

Design: Single-dose, two-way in vivo 

Strength: EQ 70 mg base 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: The BE study may be waived based on acceptable in vitro 
dissolution testing 

 

Analytes to measure (in appropriate biological fluid): Alendronate in plasma 

 

Bioequivalence based on (90% CI): Alendronate 

 

Waiver request of in vivo testing: See comments above 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of the test and reference 
products. Specifications will be determined upon review of the abbreviated new drug application 
(ANDA). 


